Most practitioners can perform SBIRT screens using WellScreen including physicians, physician assistants, nurses, pharmacists, social workers, health or substance abuse counselors, prevention specialists, and other behavioral or health staff.

Wherever there are patients seeking help, WellScreen can be your universal screening tool. Hospitals, urgent care facilities, primary care physician offices, pharmacies, health clinics on college campuses, justice programs, schools and child welfare systems are suitable venues for WellScreen.

There is robust evidence supporting the effectiveness of SBIRT across substances and implementation settings. A recently published cross-site evaluation of a national SBIRT demonstration program, which included over 1 million patients, found SBIRT associated with improvements in treatment system equity, efficiency and economy. The Community Preventive Services Task Force recently recommended the use of electronic alcohol Screening Brief Intervention (eSBI).

While research is ongoing, initial evidence suggests that SBIRT is effective specifically with opioid users. A study of Washington State’s SBIRT (WASBIRT) program found that among high risk users of prescription opioids, at a six-month follow-up, there was a 41% reduction in the days of drug use for individuals who received only a brief intervention, and a 54% reduction for the individuals who received a brief intervention, followed by brief therapy or chemical dependency treatment.

• Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed for the World Health Organization by an international group of substance abuse researchers, the ASSIST not only screens for problem or risky use of alcohol but also screens for problem or risky use of tobacco, cannabis, amphetamines, cocaine, and opiates.
• CRAFFT 2.0 (Car, Relax, Alone, Forget, Friends, Trouble) developed by Boston Children’s Hospital in collaboration with the American Academy of Pediatrics is used to screen adolescents (ages 12-18).
• Brief Opioid Overdose Knowledge (BOOK) developed by researchers at Johns Hopkins University is a twelve-question screen to assess opioid knowledge, opioid overdose knowledge, and opioid overdose response knowledge.
• The Patient Health Questionnaire 9 (PHQ9) is a 9-question instrument given to patients to screen for the presence and severity of depression.

We can customize the system to add additional screening tools to meet your organization's needs. Contact us today to learn more.

The American Medical Association (AMA) has approved several billing codes that will allow practitioners to be reimbursed for providing screening and brief intervention services. Furthermore, numerous studies demonstrate that any investments in SBIRT are more than adequately offset by money saved in the reduction of healthcare costs related to illness and injury. Each state determines Medicaid reimbursement. Detailed Information About Coding for SBIRT Reimbursement is a factsheet containing information related to coding for SBIRT activities.

Yes. Through our partnership with Redox, we can fully integrate WellScreen into existing EHRs, including Epic, Cerner and Allscripts.

Yes. Customization options include: the screeners you include, the practice workflow, EHR integration, and reporting capabilities.

Patients can complete a screen on a tablet in less than 10 minutes. If indicated, physicians (or other healthcare providers) can conduct a brief intervention or referral to treatment in 15 minutes.

WellScreen has many advantages for healthcare practices including:

• Creates additional revenue opportunities since screening and brief intervention services are reimbursable by health insurance, Medicare and Medicaid,
• Uses only evidence-based screening tools and education modules to help you screen for alcohol, smoking, cannabis, amphetamines, cocaine, opiates and depression,
• Saves your practitioners time with tablet-enabled screening questionnaires,
• Offers aggregated reporting to see results of screenings and brief interventions,
• Helps your practitioners develop customized treatment plans for patients,
• Connects your practitioners to over 2,000 licensed and accredited treatment providers for referral,
• Includes an electronic referral feature,
• Fully supported by US-based customer service team,
• Customizable to meet your health practice workflow and
• Can be fully integrated into your Electronic Health Records (EHR).

WellScreen has many advantages for patients including:

• Opens the dialog with patients about substance use and depression,
• Reduces stigma related to behavioral health conditions,
• Uncovers patients’ risk of developing a substance use disorder,
• Gives patients the opportunity for a brief intervention,
• Motivates patients to make changes,
• Matches patients to the most compatible, licensed and accredited treatment providers and
• Keeps patients on healthcare providers’ radar with 60-day follow-up feature.

WellScreen is collaborating with the National Association of Addiction Treatment Providers to incorporate a curated database of treatment providers to match patients with the most appropriate treatment resources and ensure patients find the treatment resources they need. Our database also contains all publically-funded treatment resources included in the Substance Abuse and Mental Health Services Administration’s (SAMHSA) treatment locator.

That depends. The price for an annual license starts at $2,500.

The factors that increase cost include the number of users, number of screeners included, EHR system integration, and amount of customization needed. EHR system integration and customization is usually charged as a one-time fee.

Our mission is to develop technology to promote well-being and improve lives. We do not want costs to prevent individuals from getting the help they need.

You can reach us by calling 1.844.393.7474 or emailing support@collaborateandgrow. Our support team is all U.S. based.

The WellScreen team includes partners from Johns Hopkins School of Medicine, National Association of Addiction Treatment Providers (NAATP) and staff with experience in substance abuse, prevention, public health and cloud-based health technologies. WellScreen is led by Keri-Lyn Coleman, former White House Drug Policy Advisor and National Substance Abuse Expert.